Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have been assigned a consensus recommendation of “Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $13.75.

PGNX has been the subject of several research reports. ValuEngine upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 18th. Cantor Fitzgerald restated a “buy” rating and issued a $15.00 price objective on shares of Progenics Pharmaceuticals in a research report on Wednesday, September 27th. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Finally, BidaskClub upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 9th.

Shares of Progenics Pharmaceuticals (NASDAQ PGNX) opened at $6.29 on Tuesday. The stock has a market cap of $442.00, a PE ratio of -7.96 and a beta of 3.42. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.80. Progenics Pharmaceuticals has a 1 year low of $4.60 and a 1 year high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. The business had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $3.58 million. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The firm’s revenue for the quarter was down 95.0% on a year-over-year basis. During the same quarter last year, the company posted $0.52 EPS. analysts expect that Progenics Pharmaceuticals will post -0.92 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Arizona State Retirement System increased its position in Progenics Pharmaceuticals by 0.3% in the 2nd quarter. Arizona State Retirement System now owns 36,600 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 100 shares in the last quarter. Stevens Capital Management LP increased its position in Progenics Pharmaceuticals by 2.3% in the 2nd quarter. Stevens Capital Management LP now owns 54,771 shares of the biotechnology company’s stock valued at $372,000 after acquiring an additional 1,231 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Progenics Pharmaceuticals by 3.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 60,600 shares of the biotechnology company’s stock valued at $412,000 after acquiring an additional 1,868 shares in the last quarter. Thrivent Financial For Lutherans increased its position in Progenics Pharmaceuticals by 6.8% in the 2nd quarter. Thrivent Financial For Lutherans now owns 42,380 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 2,710 shares in the last quarter. Finally, Voya Investment Management LLC increased its position in Progenics Pharmaceuticals by 12.4% in the 2nd quarter. Voya Investment Management LLC now owns 35,657 shares of the biotechnology company’s stock valued at $242,000 after acquiring an additional 3,920 shares in the last quarter. Hedge funds and other institutional investors own 84.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of “Buy” from Analysts” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/progenics-pharmaceuticals-inc-pgnx-receives-average-rating-of-buy-from-analysts/1799675.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.